Today: 29 April 2026
Browse Category

NYSE:CMA 6 October 2025 - 5 February 2026

Comerica stock price: CMA stops trading after Fifth Third merger — what shareholders own now

Comerica stock price: CMA stops trading after Fifth Third merger — what shareholders own now

Comerica shares stopped trading after Fifth Third Bancorp closed its acquisition and delisted CMA from the NYSE. Each Comerica share was converted into 1.8663 Fifth Third shares, valuing them at about $100.39 based on current prices. Fitch withdrew Comerica’s credit ratings after the deal. Fifth Third plans to finish systems integration by Labor Day, with Comerica branches keeping their name until then.
5 February 2026
Comerica stock stops trading after Fifth Third merger closes — what shareholders need to know now

Comerica stock stops trading after Fifth Third merger closes — what shareholders need to know now

Comerica shares have been suspended and will be delisted from the NYSE after its merger with Fifth Third Bancorp closed Feb. 1, according to SEC filings. Each Comerica share converts to 1.8663 Fifth Third shares. Comerica last traded near $88.67 on Jan. 30. Fifth Third, now the ninth-largest U.S. bank, will deregister Comerica’s securities and halt its SEC reporting.
3 February 2026
Fifth Third stock ticks up premarket after Comerica merger closes — what FITB investors watch next

Fifth Third stock ticks up premarket after Comerica merger closes — what FITB investors watch next

Fifth Third Bancorp shares rose 0.8% premarket Monday after it completed its $10.9 billion all-stock acquisition of Comerica, creating the ninth-largest U.S. bank with $294 billion in assets. Comerica shares will be delisted, and three former Comerica directors join Fifth Third’s board. The company expects full system and brand conversions in the third quarter. Investors await combined financials and integration updates.
2 February 2026
Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

Fifth Third–Brex Deal Puts $5.6B AI-Powered Card Platform at Center of Comerica Merger Fight

Fifth Third Bank has selected Brex to provide the technology for its commercial card program, covering $5.6 billion in annual payments. The announcement comes as Fifth Third faces lawsuits from HoldCo Asset Management and protests from community groups over its planned $10.9 billion acquisition of Comerica. The deal would create the ninth-largest U.S. bank by assets, pending regulatory approval.
Dow Dips as Fed Fears Slam Tech Stocks – Hot Economic Data Rattles Wall Street (Sept 25, 2025)

Regional Banks Roar Back? Q3 Surprises, Mega‑Mergers—and the One Risk Still Haunting 2025

The SPDR S&P Regional Banking ETF (KRE) traded at $59.82, down 0.5% intraday, with $619.3 million in outflows last week. Q3 earnings from 94 regional banks missed revenue estimates by about 1.2% on average, but shares outperformed. Fifth Third announced a $10.9 billion all-stock deal for Comerica, targeting Q1 2026 close. Trepp reported CMBS office delinquencies at a record 11.76% in October.
Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

Activist Investor Shocks Wall Street: $10.9B Comerica Sale Sparks Bank M&A Boom

HoldCo Asset Management took a 1.8% stake in Comerica in mid-2025 and criticized its management, prompting Comerica to agree to a $10.9 billion all-stock sale to Fifth Third Bancorp. The merger will create the ninth-largest U.S. bank with $288 billion in assets. Comerica shares rose 15% on the news, while Fifth Third fell 2%. HoldCo is now pressuring other regional banks for sales or changes.
Fifth Third’s Stock Jumps on Earnings Beat and Mega-Merger – Is FITB a Buy Now?

Fifth Third’s Stock Jumps on Earnings Beat and Mega-Merger – Is FITB a Buy Now?

Fifth Third Bancorp shares rose 2–3% to the low $40s on Oct. 17 after Q3 profit jumped 14% to $608 million, beating analyst estimates. The rebound followed a 4% drop the previous day amid regional bank credit fears. Net interest income climbed 7% to $1.53 billion, helped by easing deposit costs. Earlier this month, Fifth Third announced a $10.9 billion all-stock deal to acquire Comerica.
Wall Street’s Wild 48 Hours: Record Highs, AI Deals & Gold’s $4,000 Breakout

Wall Street’s Wild 48 Hours: Record Highs, AI Deals & Gold’s $4,000 Breakout

The S&P 500 and Nasdaq hit record highs before retreating Tuesday as investors took profits; the Dow also slipped. AMD surged about 24% on an OpenAI chip deal, fueling tech gains before valuations cooled. Gold topped $4,000/oz and Bitcoin reached $125,000 amid economic jitters. Fifth Third Bancorp announced an $11 billion deal to buy Comerica, sending Comerica shares up nearly 14%.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

AI Frenzy Fuels Record Wall St Rally as Shutdown Drags On – Key Market News (Oct 6-7, 2025)

The S&P 500 and Nasdaq closed at record highs Monday, while the Dow edged lower. AMD soared 24% after announcing an AI chip deal with OpenAI, boosting the semiconductor sector. Bitcoin hit a new record above $125,000. AppLovin plunged 14% on news of an SEC probe; Comerica jumped after a takeover deal.
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Fifth Third’s $10.9 B Comerica Takeover Shakes Up Banking – Will Comerica Park Get a New Name?

Fifth Third Bancorp will acquire Comerica in an all-stock deal valued at $10.9 billion, creating the ninth-largest U.S. bank with about $288 billion in assets. Comerica shareholders will receive a 20% premium, and the deal is expected to close by March 2026 pending approvals. Comerica stock jumped 15% on the news, while Fifth Third shares slipped. The merger expands Fifth Third’s reach in the Midwest and Sun Belt.
Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica’s Mega Merger Shock: Why CMA Stock Skyrocketed as Fifth Third’s $10.9 Billion Deal Reshaped Regional Banking

Comerica shares jumped as much as 15% to $81 on October 6, 2025, after Fifth Third Bancorp announced a $10.9 billion all-stock acquisition at a 20% premium. Fifth Third stock dipped 0.3%. The deal would create the ninth-largest U.S. bank with $288 billion in assets. Analysts cited regulatory tailwinds and scale benefits but warned of integration risks.

Stock Market Today

  • Ceres Power Surges Past Rolls-Royce, Nvidia, BP in FTSE 250 Rally
    April 29, 2026, 9:27 AM EDT. Ceres Power (LSE:CWR) leads the FTSE 250 stock gains in 2026 with a staggering 176% rise year-to-date, far outpacing Rolls-Royce, Nvidia and BP. The clean energy tech firm, specializing in licensing advanced solid oxide fuel cell and hydrogen technology, posted a remarkable 933% gain over the last year. Despite declining revenues - £32.6 million in 2025 down from £51.9 million the previous year - and no expected profits in 2026 or 2027, investor enthusiasm is fueled by the AI-driven data center boom. Its recent collaboration with Centrica aims to deploy efficient on-site power solutions swiftly for AI hubs and logistics centers. This positions Ceres as a crucial 'picks and shovels' provider amid the AI energy surge. However, over five years, the stock remains down 55%, prompting debate on its current valuation.

Latest article

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

Visa Stock Jumps as Earnings Beat and $20 Billion Buyback Ease Spending Fears

29 April 2026
Visa shares jumped 5% premarket Wednesday after the company beat quarterly profit estimates, raised its full-year outlook, and announced a $20 billion buyback. Adjusted net income rose to $6.3 billion, or $3.31 a share, topping forecasts. Payments volume climbed 9%, cross-border volume 12%. Visa cited resilient consumer spending but flagged Middle East tensions as a risk to travel flows.
Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

Regeneron Earnings Beat, But Eylea Still Clouds REGN Stock

29 April 2026
Regeneron Pharmaceuticals reported first-quarter revenue of $3.605 billion, up 19%, and adjusted earnings of $9.47 per share, both above analyst estimates. Dupixent sales rose 33% and Libtayo 54%, while total U.S. Eylea sales fell 10%. Shares dropped 1.1% premarket. The FDA delayed a decision on a second Eylea HD syringe manufacturer; Regeneron cut its 2026 gross-margin forecast due to repairs in Ireland.
Go toTop